Continuous infusions of meropenem in ambulatory care: Clinical efficacy, safety and stability

Laurens Manning, C. Wright, Paul Ingram, T.J. Whitmore, Christopher Heath, I. Manson, M. Page-Sharp, S. Salman, J.R. Dyer, Timothy Davis

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    Objectives: Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services. Methods: We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 g) concentrations at either 'room temperature' or 'cooled' conditions. Infusate aliquots were assayed at different time-points over 24 hours. Results: Forty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and 87%, respectively. Patients receiving 1% meropenem are likely to receive
    Original languageEnglish
    Article numbere102023
    Number of pages7
    JournalPLoS One
    Volume9
    Issue number7
    DOIs
    Publication statusPublished - 14 Jul 2014

    Fingerprint Dive into the research topics of 'Continuous infusions of meropenem in ambulatory care: Clinical efficacy, safety and stability'. Together they form a unique fingerprint.

    Cite this